Bank of America Corp
Change company Symbol lookup
Select an option...
BAC Bank of America Corp
HY Hyster-Yale Materials Handling Inc
CM Canadian Imperial Bank of Commerce
SFRFF Silver Fields Resources Inc
CHKJQ Chesapeake Energy Corp
ESPR Esperion Therapeutics Inc
VEEV Veeva Systems Inc
AVGO Broadcom Inc
IAU iShares Gold Trust

Financials : Banks | Large Cap Value
Company profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

Closing Price
Day's Change
0.60 (2.55%)
B/A Size
Day's High
Day's Low

10-day average volume:

Eli Lilly's stock rallies after a profit beat and raised outlook, although revenue fell short

6:39 am ET July 30, 2020 (MarketWatch)

Shares of Eli Lilly & Co. (LLY) rallied 2.6% in premarket trading Thursday, after the drug maker beat profit expectations and raised its full-year outlook, while revenue fell shy. Net income rose to $1.41 billion, or $1.55 a share, from $1.33 billion, or $1.44 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share rose to $1.89 from $1.50, and beat the FactSet consensus of $1.56. Revenue fell 2% to $5.50 billion, below the FactSet consensus of $5.76 billion, as volume grew 6% and realized priced declined 7%. The estimated negative impact of the COVID-19 pandemic on revenue was about $500 million, including $250 million from decreased customer buying and $250 million from delayed new patient prescription trends. Among Lilly's biggest selling drugs, Trulicity revenue rose 20% to $1.23 billion to match the FactSet consensus, while Humalog revenue fell 18% to $555.1 million to miss expectations of $610.5 million. For 2020, Lilly raised its adjusted EPS guidance range to $7.20 to $7.40 from $6.70 to $6.90, while the FactSet consensus was $6.84. The stock has run up 23.1% year to date through Wednesday, while the Dow Jones Industrial Average has slipped 7.0%.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

July 30, 2020 06:39 ET (10:39 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.